Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | LYN | P07948 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587484 | 0.87 | KDR (0.53) | LCKKDRLYNBRAFTEK | |
| SCHEMBL4586222 | 0.81 | PIKFYVE (0.57) | LCKKDRLYNBRAFTEK | |
| SCHEMBL4588535 | 0.81 | BRAF (0.57) | LCKKDRLYNPOLBBRAF | |
| SCHEMBL4586545 | 0.81 | KDR (0.52) | LCKKDRLYNBRAFTEK | |
| SCHEMBL4586898 | 0.81 | CSF1R (0.53) | LCKKDRLYNBRAFTEK | |
| SCHEMBL13269702 | 0.77 | LCK (0.61) | LCKKDRLYNPOLBKDM4E | |
| SCHEMBL4587914 | 0.76 | KDR (0.50) | LCKKDRLYNBRAFTEK | |
| SCHEMBL1828497 | 0.76 | BRAF (0.64) | LCKKDRLYNPOLBKDM4E | |
| SCHEMBL3233455 | 0.75 | LCK (0.60) | LCKKDRLYNPOLBKDM4E | |
| SCHEMBL3227999 | 0.74 | KDR (0.71) | LCKKDRLYNPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | claimed |
| EP-1858521-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2007-11-28 | — | — | EP | claimed |
| WO-2006101783-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-09-28 | — | — | WO | claimed |
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | disclosed |
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | disclosed |
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188483-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, SGK2, PTK2B | LCK 19/4885KDR 355/4885LYN 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.